SuperworthPhibro Animal Health profit margin PAHC
Gross, operating and net profit as a share of revenue over the last twelve months, from 2013.
- Net margin, 12 months
- 6.6%
- Operating margin, 12 months
- 12.8%
- Net margin on a year earlier
- +2.8 pts
- Peer median
- 13.3%
Over the twelve months to Jun 30, 2026, Phibro Animal Health kept 6.6% of its revenue as net profit, with an operating margin of 12.8% and a gross margin of 33.8%.
Five years earlier its net margin was 6.5%.
The median for 10 large drugmakers of a similar size is 13.3%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2026 | 6.6% | 12.8% | 33.8% |
| FY2025 | 3.7% | 8.5% | 30.9% |
| FY2024 | 0.2% | 5.2% | 30.8% |
| FY2023 | 3.3% | 7.3% | 30.5% |
| FY2022 | 5.2% | 8.4% | 30.3% |
| FY2021 | 6.5% | 9.0% | 32.6% |
| FY2020 | 4.2% | 8.6% | 32.1% |
| FY2019 | 6.6% | 10.1% | 32.0% |
| FY2018 | 7.9% | 12.1% | 32.5% |
| FY2017 | 8.5% | 12.8% | 32.5% |
| FY2016 | 11.0% | 11.4% | 31.8% |
| FY2015 | 8.1% | 11.7% | 31.6% |
| FY2014 | −0.5% | 9.2% | 30.0% |
| FY2013 | 3.8% | 8.7% | 27.4% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q4 FY26 | 6.6% | +2.8 pts | 12.8% | |
| Q3 FY26 | 6.3% | +3.7 pts | 12.0% | |
| Q2 FY26 | 6.3% | +4.5 pts | 11.5% | |
| Q1 FY26 | 4.8% | +3.2 pts | 10.3% | |
| Q4 FY25 | 3.7% | +3.5 pts | 8.5% | |
| Q3 FY25 | 2.7% | +1.4 pts | 8.0% | |
| Q2 FY25 | 1.7% | +0.2 pts | 7.4% | |
| Q1 FY25 | 1.7% | −0.5 pts | 6.9% | |
| Q4 FY24 | 0.2% | −3.1 pts | 5.2% | |
| Q3 FY24 | 1.3% | −1.6 pts | 5.9% | |
| Q2 FY24 | 1.5% | −2.2 pts | 5.8% | |
| Q1 FY24 | 2.1% | −2.7 pts | 5.9% |
Against its peers
Companies in Drug Manufacturers - General nearest Phibro Animal Health's size, closest first, today.
| Company | Profit margin |
|---|---|
| PAHCPhibro Animal Health | 6.6% |
| ANIPANI Pharmaceuticals | 11.1% |
| ANABAnaptysbio | n/m |
| PCRXPacira BioSciences | 2.0% |
| OMEROmeros | n/m |
| HRMYHarmony Biosciences | 18.9% |
| PBHPrestige Consumer Healthcare | 15.6% |
| AMPHAmphastar Pharmaceuticals | 10.8% |
| NRIXNurix Therapeutics | 42.0% |
| ABUSArbutus Biopharma | 84.2% |
| COLLCollegium Pharmaceutical | 5.9% |
| Peer median | 13.3% |
Where Phibro Animal Health ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Phibro Animal Health
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.